Banner for leaf pages 2

Troglitazone

Also known as Romozin and Rezulin

Troglitazone (Rezulin, Resulin, Romozin, Noscal) is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for patients with diabetes mellitus type 2. It was developed by Daiichi Sankyo Co.(Japan). In the United States, it was introduced and manufactured by Parke-Davis in the late 1990s, but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. One F.D.A. medical officer evaluating troglitazone, John Gueriguian, did not recommend its approval due to potential high liver toxicity, but a full panel of experts approved it in January 1997. Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the British market in December 1997, from the United States market in 2000, and from the Japanese market soon afterwards.

Source: Wikipedia

What is it prescribed for?

Patients are most commonly prescribed troglitazone to treat blastomycosis, rabies, west nile virus, and pick disease.

What drug interactions are known?

Do not take troglitazone if you are taking any of the following:

Critical Interactions

Significant Interactions

Ajax-loader Loading...